DOCSLIB.ORG

The Role of Membrane Transporters in Traumatic Brain Injury

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Membrane Transporters in Traumatic Brain Injury THE ROLE OF MEMBRANE TRANSPORTERS IN TRAUMATIC BRAIN INJURY: INTERVENTIONAL AND GENETIC INVESTIGATIONS by Fanuel T. Hagos BSc, Pharmacy, University of Asmara, 2006 MS, Oncological Sciences, University of Utah, 2011 Submitted to the Graduate Faculty of The School of Pharmacy in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2018 UNIVERSITY OF PITTSBURGH School of Pharmacy This thesis was presented by Fanuel T. Hagos It was defended on May 23rd, 2018 and approved by Patrick Kochanek, MD, Professor, Department of Critical Care Medicine Samuel M. Poloyac, PharmD, PhD, Professor, Department of Pharmaceutical Sciences Robert S. B. Clark, MD, Professor, Department of Critical Care Medicine Michael Tortorici, PharmD, PhD, Senior Director, Clinical Pharmacology and Pharmacometrics, CSL Behring Xiaochao Ma, PhD, Associate Professor, Department of Pharmaceutical Sciences Dissertation Advisor: Philip E. Empey, PharmD, PhD, Assistant Professor, Department of Pharmacy and Therapeutics ii THE ROLE OF MEMBRANE TRANSPORTERS IN TRAUMATIC BRAIN INJURY: INTERVENTIONAL AND GENETIC INVESTIGATIONS Fanuel T. Hagos University of Pittsburgh, 2018 Copyright © by Fanuel T. Hagos 2018 iii THE ROLE OF MEMBRANE TRANSPORTERS IN TRAUMATIC BRAIN INJURY: INTERVENTIONAL AND GENETIC INVESTIGATIONS Fanuel T. Hagos, PhD University of Pittsburgh, 2018 Traumatic brain injury (TBI) is a leading cause of death and disability in children and young adults in the US. The neurovascular unit conceptual frame work emphasizes the dynamic interplay between neurons, endothelial cells and glial cells in understanding the pathophysiology of TBI. Membrane transporters, as mediators of the movement of numerous endogenous and exogenous molecules within the neurovascular unit, are critical components of the functional neurovascular unit in TBI. The aim of this thesis is to understand the role of membrane transporters in the pathogenesis and pharmacotherapy of TBI through interventional and genetic approaches. In the first part of the thesis, we investigated the utility of inhibition of transporters with probenecid, as a therapeutic strategy to simultaneously increase the systemic and brain concentration of the anti-oxidant drug, n-acetylcysteine, and the endogenous anti-oxidant, glutathione, in TBI. This approach counters oxidative stress, a major injury mechanism in TBI. Preclinical pharmacokinetic study showed that probenecid increases plasma and brain levels of n-acetylcysteine by inhibiting OAT1 and OAT3 transporters. In rat model of pediatric TBI, n- acetylcysteine showed potential in attenuating TBI-induced learning and memory deficits. iv Probenecid caused transient motor function impairment. A combination of the two resulted in smaller cortical tissue volume loss. Optimization of dosage regimen for both drugs to enhance the effects of n-acetylcysteine and minimize the side effects of probenecid is warranted. Metabolomic and pathway analyses of cerebrospinal fluid of TBI patients treated with placebo or a combination of probenecid and n-acetylcysteine showed that the combination therapy enriched glutathione mediated anti-oxidative stress pathways. In the second part of this thesis, we examined the association of genetic alterations in monocarboxylate transporters – responsible for shuttling lactate within the neurovascular unit – with clinical outcomes. In discovery and replication cohorts, patients with one or two alternate alleles at SLC16A7 rs10506399 showed favorable outcomes. The alternate allele at the SNP was associated with increased expression of SLC16A7 which suggests that increased uptake of lactate by neurons may be beneficial in TBI. Collectively, this work has provided interventional and genetic evidence that transporters are important component of the injury mechanism and attractive therapeutic targets in TBI. Keywords: Traumatic Brain Injury, Membrane Transporters, Oxidative Stress, Lactate, Metabolomics, N-acetylcysteine, Probenecid, Monocarboxylates, Neurovascular Unit. v TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................... vi LIST OF TABLES ........................................................................................................................ xii LIST OF FIGURES ..................................................................................................................... xiii PREFACE .................................................................................................................................... xvi ABBREVIATIONS ................................................................................................................... xviii 1. Introduction ............................................................................................................................. 1 1.1. Review of the Role of Membrane Transporters in TBI ................................................... 1 1.1.1. Traumatic Brain Injury – Background ...................................................................... 1 1.1.2. Membrane Transporters in CNS – Background ........................................................ 3 1.1.3. Membrane Transporters in TBI ................................................................................ 6 1.1.4. SLC Transporters in TBI .......................................................................................... 6 1.1.4.1. Glutamate Transporters ............................................................................................. 6 1.1.4.2. MCT Transporters ................................................................................................... 12 1.1.4.3. Other SLC Transporters .......................................................................................... 20 1.1.5. ABC Transporters in TBI........................................................................................ 24 vi 1.1.6. Conclusion – TBI and Membrane Transporters...................................................... 37 1.2. Targeting Transporters to Attenuate Oxidative Stress in TBI........................................ 41 1.2.1. Oxidative Stress in TBI ........................................................................................... 41 1.2.2. Targeting Transporters with Probenecid to Simultaneously Increase Brain Levels of N-acetylcysteine and Glutathione .......................................................................................... 42 1.3. Examining the Role of SLC16A1, SLC16A3 and SLC16A7 transporters in Human TBI Patients with a Genetic Approach ............................................................................................. 44 2. Pharmacokinetic interaction between probenecid and n-acetylcysteine, in-vitro and in-vivo evidence. ....................................................................................................................................... 46 2.1. Introduction .................................................................................................................... 46 2.2. Material and Methods..................................................................................................... 48 2.2.1. Animals and treatment. ........................................................................................... 48 2.2.2. Drug administration and pharmacokinetic sampling. ............................................. 48 2.2.3. Drug analysis by LC-MS/MS. ................................................................................ 49 2.2.4. Pharmacokinetic analysis. ....................................................................................... 50 2.2.5. Cell uptake studies. ................................................................................................. 50 2.2.6. Vesicular uptake assay. ........................................................................................... 52 2.2.7. Statistical analysis. .................................................................................................. 53 2.3. Results ............................................................................................................................ 53 2.3.1. Probenecid increased n-acetylcysteine plasma and brain exposure and decreased apparent plasma clearance. .................................................................................................... 53 vii 2.3.2. N-acetylcysteine uptake by OAT3 and OAT1. ....................................................... 57 2.4. Discussion ...................................................................................................................... 62 3. The effect of a combination of n-acetylcysteine and probenecid on functional outcomes in rat, traumatic brain injury model .................................................................................................. 67 3.1. Introduction .................................................................................................................... 67 3.2. Methods .......................................................................................................................... 69 3.2.1. Animals ................................................................................................................... 69 3.2.2. Surgery .................................................................................................................... 70 3.2.3. Animal pharmacokinetics study .............................................................................
Load more

Recommended publications
  • Iron Depletion Reduces Abce1 Transcripts While Inducing The
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2019 doi:10.20944/preprints201910.0252.v1 1 Research Article 2 Iron depletion Reduces Abce1 Transcripts While 3 Inducing the Mitophagy Factors Pink1 and Parkin 4 Jana Key 1,2, Nesli Ece Sen 1, Aleksandar Arsovic 1, Stella Krämer 1, Robert Hülse 1, Suzana 5 Gispert-Sanchez 1 and Georg Auburger 1,* 6 1 Experimental Neurology, Goethe University Medical School, 60590 Frankfurt am Main; 7 2 Faculty of Biosciences, Goethe-University Frankfurt am Main, Germany 8 * Correspondence: [email protected] 9 10 Abstract: Lifespan extension was recently achieved in Caenorhabditis elegans nematodes by 11 mitochondrial stress and mitophagy, triggered via iron depletion. Conversely in man, deficient 12 mitophagy due to Pink1/Parkin mutations triggers iron accumulation in patient brain and limits 13 survival. We now aimed to identify murine fibroblast factors, which adapt their mRNA expression 14 to acute iron manipulation, relate to mitochondrial dysfunction and may influence survival. After 15 iron depletion, expression of the plasma membrane receptor Tfrc with its activator Ireb2, the 16 mitochondrial membrane transporter Abcb10, the heme-release factor Pgrmc1, the heme- 17 degradation enzyme Hmox1, the heme-binding cholesterol metabolizer Cyp46a1, as well as the 18 mitophagy regulators Pink1 and Parkin showed a negative correlation to iron levels. After iron 19 overload, these factors did not change expression. Conversely, a positive correlation of mRNA levels 20 with both conditions of iron availability was observed for the endosomal factors Slc11a2 and Steap2, 21 as well as for the iron-sulfur-cluster (ISC)-containing factors Ppat, Bdh2 and Nthl1.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Structures and Functions of Mitochondrial ABC Transporters
    ATP-binding cassette transporters: from mechanism to organism 943 Structures and functions of mitochondrial ABC transporters Theresia A. Schaedler*, Belinda Faust†, Chitra A. Shintre†, Elisabeth P. Carpenter†, Vasundara Srinivasan‡, Hendrik W. van Veen§ and Janneke Balk1 *Department of Biological Chemistry and Crop Protection, Rothamsted Research, West Common, Harpenden, AL5 2JQ, U.K. †Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, U.K. ‡LOEWE center for synthetic microbiology (SYNMIKRO) and Philipps University, D-35043 Marburg, Germany §Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, U.K. John Innes Centre and University of East Anglia, Colney Lane, Norwich, NR4 7UH, U.K. Abstract A small number of physiologically important ATP-binding cassette (ABC) transporters are found in mitochondria. Most are half transporters of the B group forming homodimers and their topology suggests they function as exporters. The results of mutant studies point towards involvement in iron cofactor biosynthesis. In particular, ABC subfamily B member 7 (ABCB7) and its homologues in yeast and plants are required for iron-sulfur (Fe-S) cluster biosynthesis outside of the mitochondria, whereas ABCB10 is involved in haem biosynthesis. They also play a role in preventing oxidative stress. Mutations in ABCB6 and ABCB7 have been linked to human disease. Recent crystal structures of yeast Atm1 and human ABCB10 have been key to identifying substrate-binding sites and transport mechanisms. Combined with in vitro and in vivo studies, progress is being made to find the physiological substrates of the different mitochondrial ABC transporters. Sequence analysis of mitochondrial ABC The ABCB7 group, which includes the ABC transporters transporters of the mitochondria Atm1 in yeast and ATM3 in Arabidopsis, Mitochondria of most eukaryote species harbour 2–4 can be found in virtually all eukaryotic species.
    [Show full text]
  • ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2008 ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Chemicals and Drugs Commons, and the Medical Sciences Commons Recommended Citation Fukuda, Yu , "ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters" (2008). Theses and Dissertations (ETD). Paper 345. http://dx.doi.org/10.21007/etd.cghs.2008.0100. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Interdisciplinary Program Research Advisor John D. Schuetz, Ph.D. Committee Linda Hendershot, Ph.D. James I. Morgan, Ph.D. Anjaparavanda P. Naren, Ph.D. Jie Zheng, Ph.D. DOI 10.21007/etd.cghs.2008.0100 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/345 ABCB6 IS A PORPHYRIN TRANSPORTER WITH A NOVEL TRAFFICKING SIGNAL THAT
    [Show full text]
  • CFTR Inhibition by Glibenclamide Requires a Positive Charge in Cytoplasmic Loop Three ⁎ Patricia Melin A, , Eric Hosy B, Michel Vivaudou B, Frédéric Becq A
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com Biochimica et Biophysica Acta 1768 (2007) 2438–2446 www.elsevier.com/locate/bbamem CFTR inhibition by glibenclamide requires a positive charge in cytoplasmic loop three ⁎ Patricia Melin a, , Eric Hosy b, Michel Vivaudou b, Frédéric Becq a a Institut de Physiologie et Biologie Cellulaires, Université de Poitiers, CNRS UMR 6187, 86022 Poitiers cedex, France b CEA, DRDC, Biophysique Moléculaire et Cellulaire, UMR CNRS/UJF/CEA 5090, 17 Rue, des Martyrs, 38054, Grenoble, France Received 20 February 2007; received in revised form 2 May 2007; accepted 14 May 2007 Available online 21 May 2007 Abstract The sulfonylurea glibenclamide is widely used as an open-channel blocker of the CFTR chloride channel. Here, we used site-directed mutagenesis to identify glibenclamide site of interaction: a positively charged residue K978, located in the cytoplasmic loop 3. Charge- neutralizing mutations K978A, K978Q, K978S abolished the inhibition of forskolin-activated CFTR chloride current by glibenclamide but not by CFTRinh-172. The charge-conservative mutation K978R did not alter glibenclamide sensitivity of CFTR current. Mutations of the neighbouring R975 (R975A, R975S, R975Q) did not affect electrophysiological and pharmacological properties of CFTR. No alteration of halide selectivity was observed with any of these CFTR mutant channels. This study identifies a novel potential inhibitor site within the CFTR molecule, and suggests a novel role of cytoplasmic loop three, within the second transmembrane domain of CFTR protein. This work is the first to report on the role of a residue in a cytoplasmic loop in the mechanism of action of the channel blocker glibenclamide.
    [Show full text]
  • Transcriptional and Post-Transcriptional Regulation of ATP-Binding Cassette Transporter Expression
    Transcriptional and Post-transcriptional Regulation of ATP-binding Cassette Transporter Expression by Aparna Chhibber DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmaceutical Sciences and Pbarmacogenomies in the Copyright 2014 by Aparna Chhibber ii Acknowledgements First and foremost, I would like to thank my advisor, Dr. Deanna Kroetz. More than just a research advisor, Deanna has clearly made it a priority to guide her students to become better scientists, and I am grateful for the countless hours she has spent editing papers, developing presentations, discussing research, and so much more. I would not have made it this far without her support and guidance. My thesis committee has provided valuable advice through the years. Dr. Nadav Ahituv in particular has been a source of support from my first year in the graduate program as my academic advisor, qualifying exam committee chair, and finally thesis committee member. Dr. Kathy Giacomini graciously stepped in as a member of my thesis committee in my 3rd year, and Dr. Steven Brenner provided valuable input as thesis committee member in my 2nd year. My labmates over the past five years have been incredible colleagues and friends. Dr. Svetlana Markova first welcomed me into the lab and taught me numerous laboratory techniques, and has always been willing to act as a sounding board. Michael Martin has been my partner-in-crime in the lab from the beginning, and has made my days in lab fly by. Dr. Yingmei Lui has made the lab run smoothly, and has always been willing to jump in to help me at a moment’s notice.
    [Show full text]
  • The Role of Mitochondrial ATP-Binding Cassette Transporter
    The Role of Mitochondrial ATP-Binding Cassette Transporter ABCB6 in Metabolism and Energy Balance By © 2019 Robert T Tessman Submitted to the graduate degree program in Toxicology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Committee Chair: Partha Kasturi, PhD Bruno Hagenbuch, PhD Hao Zhu, PhD Tiangang Li, PhD Luciano DiTacchio, PhD Date Defended: April 19th, 2019Title Page ii The dissertation committee for Robert T Tessman certifies that this is the approved version of the following dissertation: The role of Mitochondrial ATP-Binding Cassette Transporter ABCB6 in Metabolism and Energy Balance Committee Chair: Partha Kasturi, PhD Acceptance Page Date Approved: April 19th, 2019 iii Abstract Obesity and the associated health risks represent a world-wide health and financial crisis. Lack of physical activity combined with excessive caloric intake are the root cause of the problem. Despite the increased advocation for healthy lifestyle choices, the trend has yet to reverse and indeed, seems to be on the rise especially among pre- teens and adolescents, a constituent that had not been previously part of the obesity epidemic. Mitochondria are the “fuel-burners” of the body and like other combustion devices, become inefficient in the context of fuel surplus. Moreover, with chronic over-feeding, the physiological mechanisms that regulate energy balance become permanently dysfunctional leading to the progression of pathologies such as Type II diabetes and cardiovascular disease. Medical and scientific evidence confirms that mitochondria are integral to the responses necessary to adapt to over-nutrition. However, success in mitochondria- based therapies has been extremely limited in the context of metabolic diseases.
    [Show full text]
  • Anti-ABCB8 (Aa 394-693) Polyclonal Antibody (DPABH-14194) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-ABCB8 (aa 394-693) polyclonal antibody (DPABH-14194) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description ABCB8 (ATP-binding cassette, sub-family B (MDR/TAP), member 8) is a protein-coding gene. Diseases associated with ABCB8 include acute myeloid leukemia, and myeloid leukemia, and among its related super-pathways are ABC-family proteins mediated transport and SLC- mediated transmembrane transport. GO annotations related to this gene include ATPase activity, coupled to transmembrane movement of substances and transporter activity. An important paralog of this gene is TAP2. Immunogen Recombinant fragment within Human ABCB8 aa 394-693. The exact sequence is proprietary. Genbank No.: BC141836.Sequence: LMSFLVA SQTVQRSMAN LSVLFGQVVR GLSAGARVFE YMALNPCIPL SGGCCVPKEQ LRGSVTFQNV CFSYPCRPGF EVLKDFTLTL PPGKIVALVG QSGGGKTTVA SLLERFYDPT AGVVMLD Isotype IgG Source/Host Rabbit Species Reactivity Mouse, Rat, Human Purification Immunogen affinity purified Conjugate Unconjugated Applications IHC-P, WB Format Liquid Size 100 μl Buffer pH: 7.30; Constituents: 50% Glycerol, 49% PBS, PBS (without Mg2+and Ca2+) Preservative 0.05% Sodium Azide Storage Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. GENE INFORMATION 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Gene Name ABCB8 ATP-binding cassette,
    [Show full text]
  • WO 2016/090486 Al 16 June 2016 (16.06.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/090486 Al 16 June 2016 (16.06.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 5/071 (2010.01) CI2N 5/073 (2010.01) kind of national protection available): AE, AG, AL, AM, C12N 11/02 (2006.01) C12Q 1/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CA20 15/05 1297 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 9 December 2015 (09.12.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/089,5 12 9 December 2014 (09. 12.2014) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: NATIONAL RESEARCH COUNCIL OF TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, CANADA [CA/CA]; M-55, 1200 Montreal Road, Ottawa, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Ontario K lA 0R6 (CA).
    [Show full text]
  • Supplementary Table 1. Mutated Genes That Contain Protein Domains Identified Through Mutation Enrichment Analysis
    Supplementary Table 1. Mutated genes that contain protein domains identified through mutation enrichment analysis A. Breast cancers InterPro ID Mutated genes (number of mutations) IPR000219 ARHGEF4(2), ECT2(1), FARP1(1), FLJ20184(1), MCF2L2(1), NET1(1), OBSCN(5), RASGRF2(2), TRAD(1), VAV3(1) IPR000225 APC2(2), JUP(1), KPNA5(2), SPAG6(1) IPR000357 ARFGEF2(2), CMYA4(1), DRIM(2), JUP(1), KPNA5(2), PIK3R4(1), SPAG6(1) IPR000533 AKAP9(2), C10orf39(1), C20orf23(1), CUTL1(1), HOOK1(1), HOOK3(1), KTN1(2), LRRFIP1(3), MYH1(3), MYH9(2), NEF3(1), NF2(1), RSN(1), TAX1BP1(1), TPM4(1) IPR000694 ADAM12(3), ADAMTS19(1), APC2(2), APXL(1), ARID1B(1), BAT2(2), BAT3(1), BCAR1(1), BCL11A(2), BCORL1(1), C14orf155(3), C1orf2(1), C1QB(1), C6orf31(1), C7orf11(1), CD2(1), CENTD3(3), CHD5(3), CIC(3), CMYA1(2), COL11A1(3), COL19A1(2), COL7A1(3), DAZAP1(1), DBN1(3), DVL3(1), EIF5(1), FAM44A(1), FAM47B(1), FHOD1(1), FLJ20584(1), G3BP2(2), GAB1(2), GGA3(1), GLI1(3), GPNMB(2), GRIN2D(3), HCN3(1), HOXA3(2), HOXA4(1), IRS4(1), KCNA5(1), KCNC2(1), LIP8(1), LOC374955(1), MAGEE1(2), MICAL1(2), MICAL‐L1(1), MLLT2(1), MMP15(1), N4BP2(1), NCOA6(2), NHS(1), NUP214(3), ODZ1(3), PER1(2), PER2(1), PHC1(1), PLXNB1(1), PPM1E(2), RAI17(2), RAPH1(2), RBAF600(2), SCARF2(1), SEMA4G(1), SLC16A2(1), SORBS1(1), SPEN(2), SPG4(1), TBX1(1), TCF1(2), TCF7L1(1), TESK1(1), THG‐1(1), TP53(18), TRIF(1), ZBTB3(2), ZNF318(2) IPR000909 CENTB1(2), PLCB1(1), PLCG1(1) IPR000998 AEGP(3), EGFL6(2), PRSS7(1) IPR001140 ABCB10(2), ABCB6(1), ABCB8(2) IPR001164 ARFGAP3(1), CENTB1(2), CENTD3(3), CENTG1(2) IPR001589
    [Show full text]
  • Categorization and Classification of Different ABCA3 Variants Causing Interstitial Lung Disease
    Categorization and classification of different ABCA3 variants causing interstitial lung disease Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen zur Erlangung des Doktorgrades Doktor der Naturwissenschaften (Dr. rer. nat.) vorgelegt von Thomas Wittmann aus Neumarkt in der Oberpfalz, Deutschland Tübingen 2016 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen. Tag der mündlichen Qualifikation: 15.07.2016 Dekan: Prof. Dr. Wolfgang Rosenstiel 1. Berichterstatter: Prof. Dr. Dominik Hartl 2. Berichterstatter: Prof. Dr. Andreas Peschel Table of contents Table of contents Table of contents ..........................................................................................................I List of tables.................................................................................................................II List of figures................................................................................................................II Abbreviations ..............................................................................................................III Summary..................................................................................................................... V Zusammenfassung .................................................................................................... VI Publications.............................................................................................................
    [Show full text]
  • Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response
    International Journal of Molecular Sciences Article Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response Viktor Hlaváˇc 1,2 , Radka Václavíková 1,2, Veronika Brynychová 1,2, Renata Koževnikovová 3, Katerina Kopeˇcková 4, David Vrána 5 , Jiˇrí Gatˇek 6 and Pavel Souˇcek 1,2,* 1 Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic; [email protected] (V.H.); [email protected] (R.V.); [email protected] (V.B.) 2 Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic 3 Department of Oncosurgery, Medicon Services, 140 00 Prague, Czech Republic; [email protected] 4 Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic; [email protected] 5 Department of Oncology, Medical School and Teaching Hospital, Palacky University, 779 00 Olomouc, Czech Republic; [email protected] 6 Department of Surgery, EUC Hospital and University of Tomas Bata in Zlin, 760 01 Zlin, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-267-082-711 Received: 19 November 2020; Accepted: 11 December 2020; Published: 15 December 2020 Abstract: Breast cancer is the most common cancer in women in the world. The role of germline genetic variability in ATP-binding cassette (ABC) transporters in cancer chemoresistance and prognosis still needs to be elucidated. We used next-generation sequencing to assess associations of germline variants in coding and regulatory sequences of all human ABC genes with response of the patients to the neoadjuvant cytotoxic chemotherapy and disease-free survival (n = 105).
    [Show full text]